The world's first recent progress in Alzheimer's disease vaccine August 05, 2016 Source: New Kangjie Recently, scientists from the United States and Australia announced that they have successfully developed the first combined vaccine to generate antibodies targeting β-amyloid and Tau proteins to effectively prevent Alzheimer's disease. More importantly, this new vaccine is expected to be put into clinical trials within the next 3-5 years. This is undoubtedly a great news in the field of AD. As a neurodegenerative disease that occurs in the middle-aged and elderly population, Alzheimer's disease has become a major cause of threat to the health and life of the elderly. For decades, scientists have been looking for good ways to prevent and treat Alzheimer's disease, but the results have been unsatisfactory. Combined with existing research, typical pathological features of AD include: senile plaques and neurofibrillary tangles. Among them, the main component of senile plaques is β-amyloid (Aβ), and the main component of neurofibrillary tangles is hyperphosphorylated Tau protein. Therefore, how to eliminate β-amyloid and Tau protein is the starting point for the development of anti-AD drugs. According to statistics, from 2002 to 2012, there were 413 clinical trials around AD involving 244 drugs. In the end, only one drug passed the test, which means the success rate is only 0.4%. Even more unfortunately, this highly anticipated drug was finally confirmed to relieve AD symptoms for a short time. At the end of 2015, former US Secretary of State Hillary Clinton launched the Alzheimer's Disease Research Project to develop a method to treat or even cure Alzheimer's disease by 2026. In response, the National Institutes of Health invested $1.3 billion in Alzheimer's disease this year. It is with this market demand and financial support that the team of professors of the Australian medical school, Professor Nikolai Petrovsky, developed a new vaccine formulation for the first time and has obtained good test results in the mouse model of AD. This special vaccine consists of the MultiTEP platform and Advax adjuvant. Among them, MultiTEP platform can generate antibodies targeting AD pathogenic proteins; Advax adjuvant can significantly enhance antibody response. Relevant research results are published in the journal "Scientific Reports". This latest study predicts that we can use anti-β-amyloid vaccines in patients with early Alzheimer's disease, even in healthy people at risk. If the condition worsens, you can re-use the anti-Tau protein vaccine to enhance immunity. Currently, the vaccine has been shown to produce antibodies targeting beta-amyloid and Tau proteins in human brain tissue. The research team is expected to work with four biotech companies to assess the safety and effectiveness of the vaccine. Gummy Sweet Candy,Season Gummy Candy,Sweet And Sour Gummies,Sweet And Sour Gummy Bears Montreal Shantou Food Co., Ltd , https://www.montrealsnack.com